Dataset from A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome

Primary Objective:

- To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality
(composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke,
hospitalization for unstable angina) compared to placebo in type 2 diabetic participants who
recently experienced an acute coronary syndrome (ACS) event.

Secondary Objectives:

To demonstrate that when compared to placebo, lixisenatide can reduce:

- composite endpoint of CV death, non-fatal MI, non-fatal stroke, hospitalization for
unstable angina, or hospitalization for heart failure.

- composite endpoint of CV death, non-fatal MI, non-fatal stroke, hospitalization for
unstable angina, hospitalization for heart failure, or coronary revascularization
procedure.

- urinary albumin excretion (based on the urinary albumin/creatinine ratio).

To assess the safety and tolerability of lixisenatide.